H.C. Wainwright analyst Ram Selvaraju has reiterated their bullish stance on RYTM stock, giving a Buy rating yesterday.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Ram Selvaraju has given his Buy rating due to a combination of factors, even though EMANATE’s top-line results did not meet the primary efficacy endpoints across all four genetic substudies. He emphasizes that post hoc analyses still demonstrated statistically significant and clinically meaningful BMI reductions in key genetically defined subgroups, alongside a safety profile that remained consistent with prior trials and real-world use.
He also underscores that Rhythm is actively pursuing next-generation MC4R agonists, such as bivamelagon and RM-718, to target SRC1, POMC, and additional gene families identified in earlier studies, which he views as preserving long-term growth optionality. While his near-term revenue outlook is reduced and the price target is lowered from $110 to $100, he believes the company’s focused pipeline strategy and validated mechanism of action continue to justify a positive risk‑reward profile for the stock, supporting the continued Buy recommendation.
In another report released yesterday, Citi also assigned a Buy rating to the stock with a $131.00 price target.
Based on the recent corporate insider activity of 76 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of RYTM in relation to earlier this year.